THE U.S. Food and Drug Administration (FDA) is warning consumers that over-the-counter (OTC) teething products containing benzocaine pose a serious risk to infants and children, saying they should no longer be marketed and asking companies to stop selling the products for such use due to increasing evidence about benzocaine's association with deadly methemoglobinaemia.
The products are sold as gels, sprays, ointments and solutions under brand names such as Baby Orajel, Cepacol, Anbesol, Topex, Orabase, Chloraseptic & more, as well as store brands and generics.
See fda.gov for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 May 18
